search results for 
Logo

Sales

In 2012, we increased Group sales by 13% in constant currency and by 18% at actual rates to €19,290 million (20111: €16,361 million).

The chart shows the various influences on Fresenius’ Group sales. Organic growth was 6%, acquisitions contributed 8%. Divestitures reduced Group sales by 1%. Currency translation had a positive effect of 5%. More information can be found here.

There were no significant consequences from changes in product mix or pricing in 2012. In 2013, we expect no significant effects from changes in product mix. However, we cannot rule out pricing effects, especially for Fresenius Medical Care. As a result of the general budget cuts for all areas of Medicare, the reimbursement rates for dialysis services in the United States, one of our most important markets, will be reduced by 2% with effect from March 1, 2013.

Sales growth by region was as follows:

The largest regions in the Group are North America and Europe, contributing 42% and 40% of total sales, followed by Asia-Pacific with 10%, and Latin America and Africa with 6% and 2%, respectively. Germany contributed 22% to Group sales.

In North America, organic sales growth was 5%. In constant currency, sales also increased by 14%. In Europe, sales were up 12% in constant currency, with organic growth of 4%. Excellent organic growth was again achieved in Asia-Pacific with 12% and in Latin America with 22%. In these regions, sales growth in constant currency was 12% and 25%, respectively. The sales decrease in Africa was due to the volatility in Fresenius Vamed’s project business.

Sales growth in the business segments was as follows:

  • Fresenius Medical Care achieved sales of €10,741 million in 2012 (20111: €9,031 million). Organic growth was 5%, while acquisitions contributed 8%. Divestitures reduced sales by 1%. Currency translation had a positive effect of 7%. Sales include special collection efforts for services performed in prior years.
  • Fresenius Kabi increased sales by 15% to €4,539 million (2011: €3,964 million). The company achieved organic growth of 9%. Sales growth in emerging markets was again very strong. New product launches and strong demand due to ongoing supply constraints at competitors had a positive effect in the United States. Acquisitions contributed 1% to growth. Currency translation had a positive effect of 5%.
  • Fresenius Helios increased sales by 20% to €3,200 million (2011: €2,665 million). Organic growth was 5% supported by the increase in hospital admissions compared to 2011. Acquisitions contributed 17% to growth. Divestitures reduced sales growth by 2%.
  • Fresenius Vamed increased sales by 15% to €846 million (2011: €737 million). Organic growth was 5%. Acquisitions contributed 10% to growth. Sales in the project business were €506 million (2011: €494 million). Sales in the service business grew strongly by 40% to €340 million, primarily due to acquisitions (2011: €243 million).

Order intake in Fresenius Vamed’s project business again developed well: order intake increased by 9% to €657 million (2011: €604 million).

SALES BY REGION



€ in millions 2012 2011 Change Organic growth Currency translation effects Acquisitions/divestitures % of total sales
North America1 8,144 6,601 23% 5% 9% 9% 42%
Europe 7,797 6,919 13% 4% 1% 8% 40%
Asia-Pacific 1,899 1,582 20% 12% 8% 0% 10%
Latin America 1,126 899 25% 22% 0% 3% 6%
Africa 324 360 -10% -9% -1% 0% 2%
Total 19,290 16,361 18% 6% 5% 7% 100%

€ in millions 2012 2011 Change Organic growth Currency translation effects Acquisitions/divestitures % of total sales
North America1 8,144 6,601 23% 5% 9% 9% 42%
Europe 7,797 6,919 13% 4% 1% 8% 40%
Asia-Pacific 1,899 1,582 20% 12% 8% 0% 10%
Latin America 1,126 899 25% 22% 0% 3% 6%
Africa 324 360 -10% -9% -1% 0% 2%
Total 19,290 16,361 18% 6% 5% 7% 100%

SALES BY BUSINESS SEGMENT



€ in millions 2012 2011 Change Organic growth Currency translation effects Acquisitions/divestitures % of total sales
Fresenius Medical Care 1 10,741 9,031 19% 5% 7% 7% 56%
Fresenius Kabi 4,539 3,964 15% 9% 5% 1% 23%
Fresenius Helios 3,200 2,665 20% 5% 0% 15% 17%
Fresenius Vamed 846 737 15% 5% 0% 10% 4%

€ in millions 2012 2011 Change Organic growth Currency translation effects Acquisitions/divestitures % of total sales
Fresenius Medical Care 1 10,741 9,031 19% 5% 7% 7% 56%
Fresenius Kabi 4,539 3,964 15% 9% 5% 1% 23%
Fresenius Helios 3,200 2,665 20% 5% 0% 15% 17%
Fresenius Vamed 846 737 15% 5% 0% 10% 4%

Fresenius Vamed increased its order backlog by 17% to €987 million (December 31, 2011: €845 million). This assures a stable level of sustainable growth for Fresenius Vamed in the current year. Fresenius Vamed is the only business segment within the Fresenius Group whose business is significantly determined by order intake and order backlog. Driven by the continued strong demand for health care and hospital infrastructure, Fresenius Vamed was again able to sustain the trend in order intake and order backlog, as the overview below shows.

ORDER INTAKE AND ORDER BACKLOG − FRESENIUS VAMED


€ in millions 2012 2011 2010 2009 2008
Order intake 657 604 625 539 425
Order backlog (December 31) 987 845 801 679 571

€ in millions 2012 2011 2010 2009 2008
Order intake 657 604 625 539 425
Order backlog (December 31) 987 845 801 679 571


12011 sales were adjusted by -€161 million according to a U.S. GAAP accounting change. This solely relates to Fresenius Medical Care North America.
Continue reading:
Earnings structure

QUICKFINDER

History

Tools